Bank of New York Mellon Corp Acquires 9,905 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Bank of New York Mellon Corp grew its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 3.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 336,828 shares of the company’s stock after buying an additional 9,905 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.15% of Sana Biotechnology worth $549,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of SANA. Wilmington Savings Fund Society FSB acquired a new stake in shares of Sana Biotechnology in the third quarter valued at about $29,000. Stifel Financial Corp acquired a new position in shares of Sana Biotechnology during the 3rd quarter worth approximately $43,000. EP Wealth Advisors LLC bought a new stake in shares of Sana Biotechnology during the 3rd quarter worth approximately $45,000. Blue Trust Inc. boosted its holdings in shares of Sana Biotechnology by 51.0% in the 4th quarter. Blue Trust Inc. now owns 19,823 shares of the company’s stock valued at $32,000 after buying an additional 6,694 shares during the last quarter. Finally, Ieq Capital LLC bought a new position in shares of Sana Biotechnology in the fourth quarter valued at $32,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Sana Biotechnology

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the completion of the sale, the insider now owns 4,541,511 shares in the company, valued at $29,474,406.39. The trade was a 6.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 31.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

SANA has been the topic of several analyst reports. Jefferies Financial Group assumed coverage on shares of Sana Biotechnology in a research report on Friday, March 14th. They set a “buy” rating and a $7.00 price target on the stock. Citizens Jmp raised shares of Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a report on Tuesday, March 18th. TD Cowen upgraded Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Sana Biotechnology in a research note on Tuesday, March 18th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

Sana Biotechnology Stock Performance

Shares of SANA stock opened at $1.85 on Friday. The company has a market capitalization of $415.17 million, a price-to-earnings ratio of -1.32 and a beta of 1.63. Sana Biotechnology, Inc. has a 52 week low of $1.52 and a 52 week high of $10.50. The company has a 50-day simple moving average of $2.83 and a 200 day simple moving average of $3.07.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. Sell-side analysts forecast that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.